Increased level of salivary prostaglandins in patients with major depression.
We quantified the amounts of salivary prostaglandin (PG) D2, PGE2, and PGF2 alpha by radioimmunoassay in 32 patients with major depressive disorder, 16 patients with minor depressive disorder, 24 patients with neurotic disorders (panic, generalized anxiety, phobic, somatization, and obsessive compulsive), and 28 healthy controls. In the saliva of patients with major depressive disorder, the concentrations of immunoreactive PGs (PGD2, 385 +/- 71 pg/ml; PGE2, 498 +/- 105 pg/ml; PGF2 alpha, 444 +/- 100 pg/ml) were significantly higher than those of the healthy controls (PGD2, 129 +/- 18 pg/ml; PGE2, 207 +/- 25 pg/ml; PGF2 alpha, 164 +/- 17 pg/ml). On the other hand, the salivary concentrations of immunoreactive PGs from patients with minor depressive disorder or neurotic disorders were comparable to those of the controls. These results suggest that the level of salivary PGs may be an indicator of major depressive disorder.
Ohishi
K
K
Department of Psychiatry, Osaka Medical College, Japan.
Ueno
R
R
Nishino
S
S
Sakai
T
T
Hayaishi
O
O
D000328:Adult; D003866:Depressive Disorder / Q000175:diagnosis / Q000503:physiopathology*; D015237:Dinoprost; D015232:Dinoprostone; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000503:physiopathology; D015230:Prostaglandin D2; D011453:Prostaglandins / Q000032:analysis*; D011457:Prostaglandins D / Q000032:analysis; D011458:Prostaglandins E / Q000032:analysis; D011460:Prostaglandins F / Q000032:analysis; D012463:Saliva / Q000032:analysis*
D011453:Prostaglandins; D011457:Prostaglandins D; D011458:Prostaglandins E; D011460:Prostaglandins F; D015237:Dinoprost; D015232:Dinoprostone; D015230:Prostaglandin D2